Exosens Valuation
Is EXENSP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EXENSP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EXENSP (€20.49) is trading below our estimate of fair value (€46.66)
Significantly Below Fair Value: EXENSP is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EXENSP?
Key metric: As EXENSP is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is EXENSP's PS Ratio? | |
|---|---|
| PS Ratio | 2.8x |
| Sales | €353.72m |
| Market Cap | €976.35m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.1x |
| Enterprise Value/EBITDA | 12.7x |
| PEG Ratio | 15.3x |
Price to Sales Ratio vs Peers
How does EXENSP's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.7x | ||
CHG Chemring Group | 2x | 8.3% | UK£980.1m |
SNR Senior | 0.6x | 5.7% | UK£591.3m |
CHRT Cohort | 2x | 13.5% | UK£413.1m |
AVON Avon Technologies | 2x | 5.9% | UK£427.1m |
EXENSP Exosens | 2.8x | 8.6% | €976.3m |
Price-To-Sales vs Peers: EXENSP is expensive based on its Price-To-Sales Ratio (2.8x) compared to the peer average (1.7x).
Price to Sales Ratio vs Industry
How does EXENSP's PS Ratio compare vs other companies in the European Aerospace & Defense Industry?
| 3 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: EXENSP is expensive based on its Price-To-Sales Ratio (2.8x) compared to the European Aerospace & Defense industry average (1.5x).
Price to Sales Ratio vs Fair Ratio
What is EXENSP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.8x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate EXENSP's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €20.49 | €27.50 +34.2% | 5.1% | €29.00 | €25.00 | n/a | 5 |
| Nov ’25 | €19.18 | €26.90 +40.2% | 5.6% | €29.00 | €25.00 | n/a | 5 |
| Oct ’25 | n/a | €26.90 0% | 5.6% | €29.00 | €25.00 | n/a | 5 |
| Sep ’25 | €19.90 | €26.90 +35.2% | 5.6% | €29.00 | €25.00 | n/a | 5 |
| Aug ’25 | n/a | €26.90 0% | 5.6% | €29.00 | €25.00 | n/a | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
INDUS Holding
€553.3m
A private equity firm specializing in mergers and acquisitions and corporate spin-offs.
0EUH
€21.53
7D
0.8%
1Y
6.8%
Chargeurs
€232.5m
Operates as a manufacturing and services company in France, Europe, the Americas, Asia, and internationally.
0E1Y
€9.92
7D
-1.0%
1Y
15.6%
Renold
UK£97.5m
Engages in the manufacture and sale of high precision engineered products and solutions in the United Kingdom, rest of Europe, the United States, Canada, Australasia, China, India, and internationally.
RNO
UK£0.49
7D
6.1%
1Y
48.0%